We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Nanoparticle Traps Represent a Radical New Method for Treating Viral Infections

By LabMedica International staff writers
Posted on 20 Jan 2014
An Israeli biotechnology start-up company is researching a radically different approach to the problem of preventing and curing viral infections.

Traditional drug treatment attempts to destroy viruses after they already have invaded host cells and caused significant damage by initiating the disease process (fever, nausea, diarrhea, etc.) in the infected individual. A radically new approach to cure viral infections is under development at Vecoy Nanomedicines (Kiryat Ono, Israel).

Image: Virus-infected cells after treatment with Vecoy nanoparticles (indicated by arrows) (Photo courtesy of Vecoy Nanomedicines).
Image: Virus-infected cells after treatment with Vecoy nanoparticles (indicated by arrows) (Photo courtesy of Vecoy Nanomedicines).

The Vecoy (a virus decoy) is an artificial nanoparticle coated with viral receptors. The virus reacts to the nanoparticle in the same way it would to a normal target cell, but once trapped inside, it is immobilized and prevented from spreading the infection. Thus, the Vecoy technology successfully addresses the two major challenges of current medication, namely, virus resistance to treatment and toxicity effects.

Results of cell-culture and preclinical studies in Vecoy’s laboratories demonstrate neutralization of 97% percent of viruses in culture with efficacy expected to rise as the technique is refined. The method is patent pending and funding is being secured to conduct animal trials.

“Viruses are one of the most polymorphic and resilient organisms out there,” said Dr. Erez Livneh, CEO of Vecoy Nanomedicines. “They are rapidly changing, and can change anything in their genome, either by changing their exterior so our immune system would not recognize them or by changing their enzymes so that the handful of drugs we have will not affect them anymore. With the current state of overpopulation of our planet and international flights, we are now prone more than ever before to new viral pandemics which will be very hard to contain, and it is just a matter of time. We had better be in a position where we can do something about it.”

Related Links:

Vecoy Nanomedicines



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Latest BioResearch News

Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns

Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma

New Method Simplifies Preparation of Tumor Genomic DNA Libraries